Concepedia

Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience

Tina Ruggiero, Alex Proietti, Lucio Boglione, Maria Grazia Milia, Tiziano Allice, Elisa Burdino, Giancarlo Orofino, Stefano Bonora, Giovanni Di Perri, Valeria Ghisetti

Archives of Virology · 2015 · 10 citations · 21 references

DOI

Concepts

References

21

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

Journal of Hepatology · 2013 · 864 citations · Full text

, , +17

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Eric Lawitz, Mark Sulkowski, Reem Ghalib et al. · The Lancet · 2014 · 818 citations

, , +16

Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir

Christoph Sarrazin, Tara L. Kieffer, Doug J. Bartels et al. · Gastroenterology · 2007 · 614 citations · Full text

, , +17

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Ira M. Jacobson, Gregory J. Dore, Graham R. Foster et al. · The Lancet · 2014 · 436 citations

, , +16

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Michael P. Manns, Patrick Marcellin, Fred Poordad et al. · The Lancet · 2014 · 375 citations

, , +16